Eye disease Drug nanoparticles
Corneal Disease IM-CS-NPs, CS-CsA-SLN, DS-NS, CS/ TCS-SA NPs
Keratoplasty FK506 PLGA
Corneal neovascularization Flt23k NPs, Pluronic F 127 diacrylate
Viral keratitis SLNs, NLCs
Wounds of the corneal epithelium All-trans retinoic acid NPs
Corneal gene therapy Chitosan-DNA NPs, deliver plasmid
Corneal tissue engineering Nanofibrous tissue-engineered scaffolds
Glaucoma HDNP, CS-HA-NPs, (SLN)NPs
Uveitis PEG-block-PLA, NP-PEG-TAM
Retinal diseases Aerosolized NPs, Vacancy engineered mixed-valence-state cerium oxide NPs
Retinal gene therapy VMD2-eGFP, PEG-POD NPs, Compacted DNA NPs
Age-related macular degeneration PEG-LPH-NP siRNA, PLA/PLA-PEO NPs
Choroidal neovascularization bFGF-NPs, (CK30PEG)-compacted DNA NPs
CS, chitosan; CsA, cyclosporine A; HA, Hyaluronic acid; HDNP, hybrid dendrimer nanoparticle; IM, indomethacin; LPH, liposomeprotamine-hyaluronic acid; LC, lipid carrier; NPs, Nanoparticles; NS, nanoparticle suspensions; PEG, poly (ethylene) glycol; PEO, polyethylene oxide; PLA, poly (lactic acid); PLGA, poly (lactic-coglycolic acid); SA, sodium alginate; SL, solid lipid; TAM, tamoxifen; TCS, thiolated chitosan; VMD2-eGFP, retinal pigment epithelium-specific reporter vector; SLN, solid lipid nanoparticles;
Table 1: Drug nanoparticles in the ophthalmic field.